Literature DB >> 31100644

Metabolic syndrome mediates inflammatory and oxidative stress responses in patients with recurrent pregnancy loss.

Ramyar Azizi1, Mohammad Sadegh Soltani-Zangbar2, Golshan Sheikhansari3, Zahra Pourmoghadam3, Amir Mehdizadeh4, Mahdi Mahdipour5, Siamak Sandoghchian2, Shahla Danaii6, Ladan Koushaein7, Hossein Samadi Kafil8, Mehdi Yousefi9.   

Abstract

Recurrent pregnancy loss (RPL) is defined as three or more consecutive pregnancy losses prior to the 20th week of gestation. Exaggerated maternal immune response and oxidative stress status have been proposed as one of the main underlying mechanisms for RPL. The aim of this study was to evaluate the role of inflammatory pathway and oxidative stress imbalance in RPL patients with or without metabolic syndrome (MetS). 21 and 28 RPL patients with (RPL-MS) and without (RPL-NMS) metabolic syndrome were enrolled in this clinical study. 42 healthy women also were considered as the control group. The levels of IL1β, IL6, IL17, TNFα, CCL2, CXCL8 were evaluated by ELISA method. Additionally, the oxidative stress biomarkers including TAS, TOS, NO, CAT, SOD, AOPP, MPO were analyzed by spectrophotometry. The expression levels of IL1β, IL6, IL17, TNFα, CCL2, CXCL8, NFĸB, AP1, miR-21, miR-146-a, miR-223 were also assessed by real time PCR. The frequency of Th17 and T-reg cells was also measured by flow cytometry. Significant increase in the expression levels of IL1β, IL6, IL17, TNFα, CCL2, CXCL8, NFĸB, AP1 and miR-21 was observed in RPL-MS patients. Furthermore, significant decreased expression levels of FoxP3, miR-146-a and miR-223 was also observed in RPL-MS group. The levels of IL1β, IL6, IL17, TNFα, CCL2, CXCL8, NO, MPO and TOS were found to be higher in RPL-MS group compared to the RPL-NMS and healthy controls. In contrast, the level of CAT and SOD in RPL-MS patients was decreased. The frequency of Th17 and Treg cells was also higher and lower in RPL-MS patients compared to the other groups, respectively. Our results support the concept that subclinical inflammatory state, oxidative stress and metabolic syndrome play a crucial role in the etiopathogenesis of RPL assisting clinicians for pregnancy consequences prediction.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Inflammation; Metabolic syndrome; Oxidative stress; Recurrent pregnancy loss

Mesh:

Substances:

Year:  2019        PMID: 31100644     DOI: 10.1016/j.jri.2019.05.001

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  5 in total

1.  The Pharmacological Activity of the Wenjing Decoction in Recurrent Spontaneous Abortion.

Authors:  Linhui Cao; Hui Chen; Yanxia Huang; Liudan Chen; Mengru Kang; Junxiong Liang
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-13       Impact factor: 2.629

2.  miR-146a-5p-mediated suppression on trophoblast cell progression and epithelial-mesenchymal transition in preeclampsia.

Authors:  Pingping Peng; Huamei Song; Chenghong Xie; Wenfei Zheng; Huigai Ma; Dandan Xin; Jingqiong Zhan; Xiaoqing Yuan; Aihua Chen; Jing Tao; Jufang Qin
Journal:  Biol Res       Date:  2021-09-13       Impact factor: 5.612

3.  Circ-CCNB1 Modulates Trophoblast Proliferation and Invasion in Spontaneous Abortion by Regulating miR-223/SIAH1 axis.

Authors:  Meng-Yu Jing; Lai-di Xie; Xi Chen; Ying Zhou; Meng-Meng Jin; Wei-Hua He; Di-Min Wang; Ai-Xia Liu
Journal:  Endocrinology       Date:  2022-08-01       Impact factor: 5.051

4.  Differential proteomics of placentas reveals metabolic disturbance and oxidative damage participate yak spontaneous miscarriage during late pregnancy.

Authors:  Jie Pei; Shoubao Zhao; Mancai Yin; Fude Wu; Jiye Li; Guomo Zhang; Xiaoyun Wu; Pengjia Bao; Lin Xiong; Weiru Song; Yang Ba; Ping Yan; Rende Song; Xian Guo
Journal:  BMC Vet Res       Date:  2022-06-27       Impact factor: 2.792

5.  miR‑146a improves hepatic lipid and glucose metabolism by targeting MED1.

Authors:  Kun Li; Bao Zhao; Diandian Wei; Wenrui Wang; Yixuan Cui; Lisheng Qian; Guodong Liu
Journal:  Int J Mol Med       Date:  2019-12-27       Impact factor: 4.101

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.